Institutional members access full text with Ovid®

Share this article on:

The role of systemic therapies in the management of melanoma brain metastases

Lyle, Megana,b; Long, Georgina V.a,b

doi: 10.1097/CCO.0000000000000057

Purpose of review Brain metastases in metastatic melanoma are highly prevalent and are associated with significant morbidity and a poor prognosis. Local therapy (surgery or radiotherapy) has been the mainstay of treatment, due in part to the lack of efficacy of systemic therapy. This review will focus on new systemic therapies for metastatic melanoma and their evolving role in the management of brain metastases.

Recent findings BRAF inhibitors have demonstrated efficacy in active (i.e. untreated or progressing) brain metastases in BRAF V600 mutated metastatic melanoma. The cytotoxic T lymphocyte antigen 4 (CTLA-4) antibody, ipilimumab, has also shown activity, particularly in asymptomatic metastases. Studies of programmed death 1/programmed death ligand 1 checkpoint inhibitors and combination BRAF and MEK inhibitor therapy in brain metastases are planned. Emerging evidence on the molecular biology of melanoma brain metastases, particularly the role of the phosphatidylinositol 3-kinase-AKT pathway, may identify additional therapeutic targets.

Summary The development of systemic therapy effective in controlling both intra-cranial and extra-cranial melanoma metastases has resulted in a change in the paradigm of management. More research is required in patients with active brain metastases to improve patient outcomes, including studies early in the development of novel therapies, and studies to determine the safe and effective combination or sequencing of local and systemic therapies.

aMelanoma Institute Australia

bThe University of Sydney, Sydney, Australia

Correspondence to Dr Georgina V. Long, MB, BS, PhD, FRACP, Melanoma Institute Australia and The University of Sydney, 40 Rocklands Rd, North Sydney, NSW 2060, Australia. Tel: +61 2 9911 7200; e-mail:

© 2014 Lippincott Williams & Wilkins, Inc.